Ethyreal launches with $101M, aiming to compete in Tepezza’s arena: Venture Report

Newly launched Ethyreal revealed this week that it has raised $101 million across two venture rounds that will drive its long-acting therapy for Graves disease and thyroid eye disease into the clinic this year.

Backed initially by Atlas Venture and Medicxi Ventures, Ethyreal Bio Inc. is advancing long-acting anti-TSHR antibody ETHY-001 to treat both disorders. Nandi Life Sciences and Checkpoint Capital joined those firms in Ethyreal’s $41 million series A round; Avoro Capital joined the syndicate to lead its $60 million series B...